How to fool a wonder drug: truncate and dimerize

Miriam Molina-Arcas; Julian Downward

doi:10.1016/j.ccr.2011.12.017

How to fool a wonder drug: truncate and dimerize

Cancer Cell. 2012 Jan 17;21(1):7-9. doi: 10.1016/j.ccr.2011.12.017.

Authors

Miriam Molina-Arcas¹, Julian Downward

Affiliation

¹ Signal Transduction Laboratory, Cancer Research UK London Research Institute, UK.

PMID: 22264784
DOI: 10.1016/j.ccr.2011.12.017

Abstract

In a recent paper, Poulikakos et al. describe a new and potentially common mechanism whereby melanomas develop resistance to the BRAF inhibitor vemurafenib by expressing truncated forms of BRAF(V600E) that can dimerize in the absence of activated RAS. Will it be possible to block this with improved BRAF inhibitor design?

Publication types

Comment

Grants and funding

15680/CRUK_/Cancer Research UK/United Kingdom